• Clear Street

  Participated · Series B · Apr 2023

  Clear Street operates as a broker of securities and derivatives, serving clients with trading and related capital-markets services. According to documents reviewed by Bloomberg, the company generated approximately $940 million in net revenue in the twelve months ended 30 September 2025. It also posted a 2024 net profit of $89 million, a sharp turnaround from a $18 million loss in 2023. Executive Chairman Uriel Cohen and CEO Ed Tilly, the former chief executive of Cboe Global Markets, lead the company. Clear Street’s latest fundraising valued the business at $12 billion and paves the way for a near-term IPO filing. The firm has reportedly engaged Goldman Sachs, Morgan Stanley, and UBS as advisers for the prospective public listing.

• Iridia

  Participated · Series B · Mar 2021

  Iridia, headquartered in Carlsbad, CA, is developing integrated DNA-based data storage that combines proprietary enzymology and semiconductor technology to write, store, and read information in synthetic DNA. Its core approach uses enzyme-based chemistry and programmable semiconductor systems to add DNA-based bits, aiming for orders-of-magnitude higher density and durability than conventional archival technologies. The company positions its solution as more energy-efficient, cost-competitive, and secure, with a much smaller physical and carbon footprint than current data-center storage. Iridia is working toward commercially viable, decodable DNA storage by developing working prototypes that can manipulate single DNA molecules and read them back using the same device. Current plans funded by new financing include further validation of the technology, prototype development, and doubling headcount and physical footprint to accelerate growth. Iridia develops an integrated DNA-based memory chip that combines semiconductor technology with proprietary enzyme-based chemistry to write, store, and read digital data using synthetic DNA as the storage medium. The company’s chip-level approach aims to increase data density and durability while dramatically reducing the physical and carbon footprints of commercial data centers. Iridia says its technology can encode and read DNA on-chip, eliminating the need for complex storage infrastructure and laboratory sequencing. Management projects a dramatic cost reduction in encoding and retrieving 1 TB of DNA-stored data from more than $1 million today to less than $1. The recent financing is intended to accelerate development of the world’s first commercially viable DNA memory chips and to demonstrate scalability. Iridia is headquartered in Carlsbad, California.

No current team members are available.